These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Wiseman LR; Spencer CM Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314 [TBL] [Abstract][Full Text] [Related]
7. Clinical status and optimal use of the cardioprotectant, dexrazoxane. Blum RH Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365 [No Abstract] [Full Text] [Related]
8. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656 [TBL] [Abstract][Full Text] [Related]
9. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. Lipshultz SE J Clin Oncol; 1996 Feb; 14(2):328-31. PubMed ID: 8636739 [No Abstract] [Full Text] [Related]
10. Overview and historical development of dexrazoxane. Hellmann K Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824 [TBL] [Abstract][Full Text] [Related]
11. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870 [TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. Anderson B Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251 [TBL] [Abstract][Full Text] [Related]
13. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation]. Goey AK; Schellens JH; Beijnen JH; Huitema AD Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024 [TBL] [Abstract][Full Text] [Related]
14. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Wexler LH Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829 [TBL] [Abstract][Full Text] [Related]
15. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer]. Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973 [TBL] [Abstract][Full Text] [Related]
16. A drug for prevention of anthracycline-induced cardiac toxicity. Med Lett Drugs Ther; 1991 Sep; 33(852):85-6. PubMed ID: 1908544 [No Abstract] [Full Text] [Related]
17. Drug may protect children's hearts from chemotherapy. McBride D ONS Connect; 2010 Dec; 25(12):15. PubMed ID: 21214085 [No Abstract] [Full Text] [Related]
18. [The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)]. Sauer H Strahlenther Onkol; 1997 Jan; 173(1):51-2. PubMed ID: 9082586 [No Abstract] [Full Text] [Related]
19. [Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology]. Kolygin BA Vopr Onkol; 2002; 48(1):110-2. PubMed ID: 12101558 [No Abstract] [Full Text] [Related]
20. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Hellmann K Support Care Cancer; 1996 Jul; 4(4):305-7. PubMed ID: 8829310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]